PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
HROW vs. HALO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between HROW and HALO is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

HROW vs. HALO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%AugustSeptemberOctoberNovemberDecember2025
33.55%
0.70%
HROW
HALO

Key characteristics

Sharpe Ratio

HROW:

2.76

HALO:

1.47

Sortino Ratio

HROW:

4.04

HALO:

2.02

Omega Ratio

HROW:

1.49

HALO:

1.31

Calmar Ratio

HROW:

2.55

HALO:

1.37

Martin Ratio

HROW:

13.42

HALO:

4.83

Ulcer Index

HROW:

17.72%

HALO:

12.28%

Daily Std Dev

HROW:

86.61%

HALO:

40.61%

Max Drawdown

HROW:

-99.46%

HALO:

-74.26%

Current Drawdown

HROW:

-76.60%

HALO:

-13.29%

Fundamentals

Market Cap

HROW:

$1.15B

HALO:

$7.11B

EPS

HROW:

-$0.95

HALO:

$3.02

Total Revenue (TTM)

HROW:

$132.78M

HALO:

$717.32M

Gross Profit (TTM)

HROW:

$97.67M

HALO:

$564.43M

EBITDA (TTM)

HROW:

$2.55M

HALO:

$443.38M

Returns By Period

In the year-to-date period, HROW achieves a -3.76% return, which is significantly lower than HALO's 16.84% return. Over the past 10 years, HROW has outperformed HALO with an annualized return of 15.98%, while HALO has yielded a comparatively lower 14.66% annualized return.


HROW

YTD

-3.76%

1M

-3.61%

6M

33.54%

1Y

232.54%

5Y*

37.51%

10Y*

15.98%

HALO

YTD

16.84%

1M

16.06%

6M

0.70%

1Y

63.29%

5Y*

23.53%

10Y*

14.66%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

HROW vs. HALO — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HROW
The Risk-Adjusted Performance Rank of HROW is 9595
Overall Rank
The Sharpe Ratio Rank of HROW is 9797
Sharpe Ratio Rank
The Sortino Ratio Rank of HROW is 9797
Sortino Ratio Rank
The Omega Ratio Rank of HROW is 9595
Omega Ratio Rank
The Calmar Ratio Rank of HROW is 9393
Calmar Ratio Rank
The Martin Ratio Rank of HROW is 9494
Martin Ratio Rank

HALO
The Risk-Adjusted Performance Rank of HALO is 8484
Overall Rank
The Sharpe Ratio Rank of HALO is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of HALO is 8181
Sortino Ratio Rank
The Omega Ratio Rank of HALO is 8484
Omega Ratio Rank
The Calmar Ratio Rank of HALO is 8585
Calmar Ratio Rank
The Martin Ratio Rank of HALO is 8181
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

HROW vs. HALO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for HROW, currently valued at 2.76, compared to the broader market-2.000.002.002.761.47
The chart of Sortino ratio for HROW, currently valued at 4.04, compared to the broader market-4.00-2.000.002.004.004.042.02
The chart of Omega ratio for HROW, currently valued at 1.49, compared to the broader market0.501.001.502.001.491.31
The chart of Calmar ratio for HROW, currently valued at 2.55, compared to the broader market0.002.004.006.002.551.37
The chart of Martin ratio for HROW, currently valued at 13.42, compared to the broader market-10.000.0010.0020.0013.424.83
HROW
HALO

The current HROW Sharpe Ratio is 2.76, which is higher than the HALO Sharpe Ratio of 1.47. The chart below compares the historical Sharpe Ratios of HROW and HALO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00AugustSeptemberOctoberNovemberDecember2025
2.76
1.47
HROW
HALO

Dividends

HROW vs. HALO - Dividend Comparison

Neither HROW nor HALO has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

HROW vs. HALO - Drawdown Comparison

The maximum HROW drawdown since its inception was -99.46%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HROW and HALO. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-76.60%
-13.29%
HROW
HALO

Volatility

HROW vs. HALO - Volatility Comparison

Harrow Health, Inc. (HROW) has a higher volatility of 17.58% compared to Halozyme Therapeutics, Inc. (HALO) at 8.42%. This indicates that HROW's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
17.58%
8.42%
HROW
HALO

Financials

HROW vs. HALO - Financials Comparison

This section allows you to compare key financial metrics between Harrow Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab